Immunic (NASDAQ:IMUX) Given “Buy” Rating at HC Wainwright

Immunic (NASDAQ:IMUX)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They presently have a $10.00 price target on the stock.

Other research analysts have also issued reports about the company. D. Boral Capital restated a “buy” rating and issued a $17.00 price target on shares of Immunic in a research report on Thursday. StockNews.com lowered Immunic from a “hold” rating to a “sell” rating in a research report on Monday, February 10th. One analyst has rated the stock with a sell rating, six have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Immunic presently has a consensus rating of “Buy” and a consensus price target of $12.67.

Immunic Stock Performance

NASDAQ IMUX opened at $1.18 on Friday. The stock has a fifty day moving average of $1.02 and a 200-day moving average of $1.26. The stock has a market capitalization of $106.29 million, a P/E ratio of -0.96 and a beta of 1.87. Immunic has a 52 week low of $0.92 and a 52 week high of $2.11.

Institutional Trading of Immunic

Institutional investors have recently modified their holdings of the company. Invesco Ltd. bought a new stake in shares of Immunic in the fourth quarter valued at about $37,000. Virtu Financial LLC acquired a new stake in shares of Immunic in the third quarter valued at about $50,000. HB Wealth Management LLC acquired a new stake in shares of Immunic in the fourth quarter valued at about $81,000. Barclays PLC acquired a new stake in shares of Immunic in the fourth quarter valued at about $84,000. Finally, Jane Street Group LLC increased its position in shares of Immunic by 121.4% in the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after acquiring an additional 38,553 shares during the last quarter. 51.82% of the stock is currently owned by institutional investors.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.